Zenas BioPharma Inc. (NASDAQ: ZBIO ) is one of the best IPO stocks with huge upside potential . On June 2, Zenas announced positive results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease. The study met its primary and all key secondary endpoints, demonstrating a 56% reduction in flare risk compared to placebo and a significant decrease in glucocorticoid use and related toxicities.

The findings, presented at the EULAR 2026 Congress and published in the New England Journal of Medicine, highlight the drug's potential as a first-line therapy. The trial, the largest ever conducted for this disease, showed that over 73% of treated patients remained flare-free through 52 weeks with a safety profile comparable to the placebo.

Following these successful results, Zenas BioPharma Inc. (NASDAQ:ZBIO) submitted a Biologics License Application to the FDA in May. The company continues to advance its clinical pipeline, with additional data expected later this year from its Phase 2 trial for systemic lupus erythematosus.

Zenas BioPharma Inc. (NASDAQ:ZBIO) is a clinical-stage company focused on developing transformative therapies for autoimmune diseases. Their pipeline features late-stage candidates like obexelimab and orelabrutinib, alongside several earlier-stage programs targeting chronic inflammatory conditions.

While we acknowledge the potential of ZBIO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy .

Disclosure: None. Follow Insider Monkey on Google News .